Pinuccia Valagussa Selected Research

Therapeutics

1/2022	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer.
10/2017	Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials.
1/2012	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
5/2009	Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
12/2005	Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
7/2003	Role of proliferation in HER2 status predicted response to doxorubicin.
3/2003	Refined measurement of outcome for adjuvant breast carcinoma therapy.
2/2003	HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pinuccia Valagussa Research Topics

Disease

28	Breast Neoplasms (Breast Cancer) 01/2022 - 02/2003
16	Neoplasms (Cancer) 01/2022 - 01/2002
4	Inflammatory Breast Neoplasms 06/2016 - 01/2010
4	Hodgkin Disease (Hodgkin's Disease) 07/2011 - 07/2004
3	Pathologic Complete Response 01/2017 - 10/2005
2	Neutropenia 01/2018 - 06/2016
2	Multiple Myeloma 03/2013 - 09/2003
2	Neoplasm Metastasis (Metastasis) 03/2010 - 04/2004
1	Stomatitis 01/2018
1	Hypersensitivity (Allergy) 01/2018
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2017
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2017
1	Febrile Neutropenia 06/2016
1	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2016
1	Triple Negative Breast Neoplasms 07/2014
1	Thrombosis (Thrombus) 05/2014
1	Venous Thrombosis (Deep-Vein Thrombosis) 05/2014
1	Sarcoma (Soft Tissue Sarcoma) 03/2012
1	Heart Failure 01/2010
1	Breast Cancer 3 01/2010
1	Familial ependymoma 04/2004
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2003
1	Disease Progression 01/2002
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2002
1	Esophageal Squamous Cell Carcinoma 01/2002

Drug/Important Bio-Agent (IBA)

11	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2012 - 02/2003
8	Trastuzumab (Herceptin)FDA Link 01/2022 - 01/2010
8	Fluorouracil (Carac)FDA LinkGeneric 04/2012 - 05/2004
8	Methotrexate (Mexate)FDA LinkGeneric 04/2012 - 05/2004
8	Cyclophosphamide (Cytoxan)FDA LinkGeneric 07/2011 - 05/2004
6	Paclitaxel (Taxol)FDA LinkGeneric 03/2018 - 10/2005
5	pertuzumabIBA 01/2022 - 01/2012
5	AnthracyclinesIBA 01/2019 - 10/2005
3	Hormones (Hormone)IBA 01/2022 - 01/2012
3	Docetaxel (Taxotere)FDA Link 01/2017 - 01/2012
3	Estrogen ReceptorsIBA 04/2012 - 12/2005
3	Vinblastine (Vinblastine Sulfate)FDA Link 07/2011 - 07/2004
3	Bleomycin (Blenoxane)FDA LinkGeneric 07/2011 - 07/2004
3	Dacarbazine (DIC)FDA LinkGeneric 07/2011 - 07/2004
2	palbociclibIBA 01/2022 - 01/2018
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2017
2	taxaneIBA 01/2019 - 04/2012
2	human ERBB2 proteinIBA 03/2018 - 02/2003
2	Pharmaceutical PreparationsIBA 05/2014 - 01/2012
2	Capecitabine (Xeloda)FDA Link 04/2012 - 10/2006
2	Prednisone (Sone)FDA LinkGeneric 07/2011 - 05/2005
2	Vincristine (Oncovin)FDA LinkGeneric 07/2011 - 05/2005
2	Procarbazine (Matulane)FDA Link 07/2011 - 05/2005
2	Monoclonal AntibodiesIBA 01/2010 - 02/2003
1	Estrogens (Estrogen)FDA Link 01/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	130-nm albumin-bound paclitaxelIBA 03/2018
1	Albumin-Bound Paclitaxel FDA Link 03/2018
1	Phenobarbital (Luminal)FDA Link 03/2018
1	Aromatase InhibitorsIBA 01/2018
1	Alanine Transaminase (SGPT)IBA 01/2018
1	Fulvestrant (Faslodex)FDA Link 01/2018
1	antineoplaston A10 (A 10)IBA 06/2016
1	Indicators and Reagents (Reagents)IBA 06/2016
1	Progesterone Receptors (Progesterone Receptor)IBA 06/2016
1	Brentuximab VedotinIBA 01/2016
1	Bortezomib (Velcade)FDA Link 03/2013
1	Dexamethasone (Maxidex)FDA LinkGeneric 03/2013
1	exemestane (Aromasin)FDA Link 04/2012
1	Etoposide (VP 16)FDA LinkGeneric 07/2011
1	Hyaluronic Acid (Hyaluronan)IBA 01/2008
1	CarbamatesIBA 10/2006
1	ProdrugsIBA 10/2006
1	ParaffinIBA 10/2005
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 10/2005
1	Mechlorethamine (Nitrogen Mustard)FDA Link 05/2005
1	Biological ProductsIBA 07/2003
1	Therapeutic UsesIBA 02/2003
1	Dihydrotachysterol (AT 10)IBA 01/2002

Therapy/Procedure

14	Drug Therapy (Chemotherapy) 01/2022 - 01/2002
10	Neoadjuvant Therapy 01/2022 - 07/2003
8	Therapeutics 01/2022 - 02/2003
5	Radiotherapy 07/2011 - 01/2002
3	Stem Cell Transplantation 01/2020 - 09/2003
3	Adjuvant Chemotherapy 03/2012 - 02/2003
3	Mastectomy (Mammectomy) 03/2010 - 01/2004
2	Salvage Therapy 01/2022 - 07/2010